Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Temozolomide, or Bevacizumab with Radiation in Pediatric High-Grade Glioma
NCT01236560Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Jun 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of vorinostat in glioma, sponsored by National Cancer Institute. Started Jan 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01236560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236560.